JP2009515858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515858A5 JP2009515858A5 JP2008539452A JP2008539452A JP2009515858A5 JP 2009515858 A5 JP2009515858 A5 JP 2009515858A5 JP 2008539452 A JP2008539452 A JP 2008539452A JP 2008539452 A JP2008539452 A JP 2008539452A JP 2009515858 A5 JP2009515858 A5 JP 2009515858A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- lower alkyl
- acyl
- formula
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, amino Chemical group 0.000 claims description 80
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 102100035427 Forkhead box protein O1 Human genes 0.000 claims description 11
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000005945 translocation Effects 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 4
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 101000601661 Homo sapiens Paired box protein Pax-7 Proteins 0.000 claims description 2
- 102100037503 Paired box protein Pax-7 Human genes 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- IIQIEMHSDLLZQA-QZPVEUDVSA-N n-((9s,10r,11r,13r)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methyl-benzamide Chemical compound CN([C@H]1[C@@]([C@]2(C)O[C@H]1N1C3=CC=CC=C3C3=C4C(=O)NCC4=C4C5=CC=CC=C5N2C4=C31)(C)OC)C(=O)C1=CC=CC=C1 IIQIEMHSDLLZQA-QZPVEUDVSA-N 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 230000005865 ionizing radiation Effects 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000002015 acyclic group Chemical group 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000001142 anti-diarrhea Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 2
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 2
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 0 BC(*)(C=C1)C=Cc2c1c(c(C(*)*)c1*=O)c3[n]2[C@](C)([C@@]([C@@](C2)N(*)*)O*)O[C@]2[n]2c(I=CC(*)(*)C=C4)c4c1c32 Chemical compound BC(*)(C=C1)C=Cc2c1c(c(C(*)*)c1*=O)c3[n]2[C@](C)([C@@]([C@@](C2)N(*)*)O*)O[C@]2[n]2c(I=CC(*)(*)C=C4)c4c1c32 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 125000001485 cycloalkadienyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960005493 difenoxin Drugs 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000008414 paregoric Substances 0.000 description 1
- 229940069533 paregoric Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73622205P | 2005-11-14 | 2005-11-14 | |
| US60/736,222 | 2005-11-14 | ||
| PCT/EP2006/068410 WO2007054579A1 (en) | 2005-11-14 | 2006-11-13 | Staurosporine derivatives for use in alveolar rhabdomyosarcoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515858A JP2009515858A (ja) | 2009-04-16 |
| JP2009515858A5 true JP2009515858A5 (enExample) | 2010-01-07 |
| JP5308820B2 JP5308820B2 (ja) | 2013-10-09 |
Family
ID=37758863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539452A Expired - Fee Related JP5308820B2 (ja) | 2005-11-14 | 2006-11-13 | 胞巣状横紋筋肉腫に使用するためのスタウロスポリン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7973032B2 (enExample) |
| EP (1) | EP1951255A1 (enExample) |
| JP (1) | JP5308820B2 (enExample) |
| KR (1) | KR20080067654A (enExample) |
| CN (1) | CN101304749A (enExample) |
| AU (1) | AU2006313724B2 (enExample) |
| BR (1) | BRPI0618571A2 (enExample) |
| CA (1) | CA2629478C (enExample) |
| RU (1) | RU2443421C2 (enExample) |
| WO (1) | WO2007054579A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025132479A1 (en) * | 2023-12-18 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Flt3 inhibitor for modulating macrophages polarization |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| AU6714396A (en) * | 1995-07-28 | 1997-02-26 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
| CA2253608A1 (en) * | 1996-05-01 | 1997-11-06 | Louis Vignati | Therapeutic treatment for vegf related diseases |
| PT1441737E (pt) * | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| DE602004030265D1 (de) * | 2003-09-19 | 2011-01-05 | Novartis Ag | Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin |
| RU2269315C2 (ru) * | 2004-05-24 | 2006-02-10 | Рашид Кямиль Оглы Гусейнов | Способ соединения сосудов и устройство для герметизации надреза сосуда и перерезания стенки сосуда |
-
2006
- 2006-11-13 JP JP2008539452A patent/JP5308820B2/ja not_active Expired - Fee Related
- 2006-11-13 WO PCT/EP2006/068410 patent/WO2007054579A1/en not_active Ceased
- 2006-11-13 BR BRPI0618571-1A patent/BRPI0618571A2/pt not_active IP Right Cessation
- 2006-11-13 CN CNA2006800384359A patent/CN101304749A/zh active Pending
- 2006-11-13 CA CA2629478A patent/CA2629478C/en not_active Expired - Fee Related
- 2006-11-13 AU AU2006313724A patent/AU2006313724B2/en not_active Ceased
- 2006-11-13 EP EP06829981A patent/EP1951255A1/en not_active Withdrawn
- 2006-11-13 RU RU2008123382/15A patent/RU2443421C2/ru not_active IP Right Cessation
- 2006-11-13 KR KR1020087011406A patent/KR20080067654A/ko not_active Ceased
- 2006-11-13 US US12/090,626 patent/US7973032B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507412A5 (enExample) | ||
| RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
| US20110190312A1 (en) | Combinations Comprising Epothilones and Protein Tyrosine Kinase Inhibitors and Pharmaceutical Uses Thereof | |
| US20220323436A1 (en) | Protein kinase c inhibitors for treatment of uveal melanoma | |
| RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием | |
| US20040132754A1 (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
| WO2008090327A1 (en) | New combination for use in the treatment of cancer | |
| US20120053559A1 (en) | Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation | |
| Mantadakis et al. | Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| JP2003516994A5 (enExample) | ||
| US20140024687A1 (en) | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists | |
| CN101677970A (zh) | 铁螯合剂用于治疗心肌梗塞的用途 | |
| JP5308820B2 (ja) | 胞巣状横紋筋肉腫に使用するためのスタウロスポリン誘導体 | |
| CN117177752A (zh) | 用于治疗mpnst的化合物和组合物 | |
| WO2006021456A1 (en) | Combination comprising a staurosporine and a cyp3a4 inhibitor | |
| US20050159404A1 (en) | Organic compound | |
| JP2007530567A (ja) | エポチロン及びカルボプラチンを用いる併用療法 | |
| JP2021512857A (ja) | Ｎｍｄａ受容体アゴニストの投与方法 | |
| MX2008006287A (es) | Derivados de estaurosporina para utilizarse en rabdomiosarcoma alveolar. | |
| JP2004099604A (ja) | マクロライド化合物による心疾患治療剤 | |
| RU2007125565A (ru) | Применение стауроспорина для лечения множественной миеломы | |
| WO2006032537A2 (en) | Use of epothilones in the treatment of bone metastases and bone tumors or cancers | |
| WO2008043811A1 (en) | Staurosporine derivatives and radiation | |
| HK1109059B (en) | Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof |